Medicine for treating hypercholesterolemia and preparation method thereof

The cholesterol absorption inhibitor is synthesized by glutaric anhydride and fluorobenzene, and a bile chelating agent is prepared by polymer technology, combining emulsifiers to form hypercholesterolemia drugs, which solves the problems of high preparation costs and poor bile acid secretion control in the prior art. , achieving more effective bile acid management and cardiovascular health improvement.

CN119033944APending Publication Date: 2024-11-29QIANNAN COLLEGE OF ETHNIC MEDICINE
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411148341.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing hypercholesterolemia drugs are costly and have poor bile acid secretion control effect, which leads to an increase in the risk of gallstones and affects the treatment effect.

Method used

Use glutaric anhydride and fluorobenzene to synthesize cholesterol absorption inhibitors, and prepare bile chelating agents through basic polymers, crosslinking agents and functional monomers, combine emulsifiers to form hypercholesterolemia drugs, control bile acid secretion, and avoid excessive absorption of income. Blood.

Benefits of technology

It reduces the difficulty of synthesis of cholesterol absorption inhibitors, improves the cost-effectiveness of drug preparation, improves the functionality of bile acids, reduces the risk of gallstones, and improves cardiovascular health and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033944A_ABST
    Figure CN119033944A_ABST
Patent Text Reader

Abstract

The invention discloses a medicine for hypercholesterolemia and a preparation method, and relates to the technical field of cholesterol medicines. The composition comprises a cholesterol absorption inhibitor and a bile acid chelating agent, the cholesterol absorption inhibitor comprises glutaric anhydride and fluorobenzene, and the bile chelating agent comprises a base polymer, a cross-linking agent and a functional monomer; according to the preparation method, the cholesterol absorption inhibitor is prepared through the Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis and lactonization reaction of glutaric anhydride and fluorobenzene, so that the synthesis difficulty of the cholesterol absorption inhibitor is reduced, and the preparation cost of the hypercholesteremia medicine is improved; the bile chelating agent prepared from the basic polymer, the cross-linking agent and the functional monomer can better control excessive secretion of bile acid, improve the functionality of the bile acid, avoid gall-stone and prevent the bile acid from being excessively absorbed into blood, so that the effect of the prepared hypercholesterolemia medicine is improved, cardiovascular health is improved, and the curative effect of the hypercholesterolemia medicine is improved. The risk of cardiovascular diseases is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of cholesterol medicines, in particular to a medicine for treating hypercholesterolemia and a preparation method thereof. Background Art

[0002] Hypercholesterolemia refers to elevated cholesterol levels in the blood. The causes of hypercholesterolemia include genetics, unhealthy lifestyles, drugs, other diseases, etc. It is more common in middle-aged and elderly people, obese people, and patients with diabetes and hypertension. The disease usually has no obvious symptoms and is only discovered during physical examinations. However, if hypercholesterolemia is not controlled, as the disease progresses, it can cause xanthomas, strokes, and other problems.

[0003] However, the existing hypercholesterolemia treatment drugs still have some defects:

[0004] In the process of preparing hypercholesterolemia drugs, the synthesis of cholesterol absorption inhibitors in hypercholesterolemia drugs is difficult, resulting in a high preparation cost of hypercholesterolemia drugs. At the same time, the bile sequestrants in therapeutic drugs are less effective in controlling bile acid secretion, resulting in excessive bile acid secretion in the patient's body, which is prone to stones and further leads to poor effects of hypercholesterolemia drugs.

[0005] In view of the above problems, the inventors proposed a drug for hypercholesterolemia and a preparation method thereof to solve the above problems. Summary of the invention

[0006] In order to solve the above problems, the present invention aims to provide a drug for hypercholesterolemia and a preparation method thereof.

[0007] In order to solve the above technical problems, the present invention adopts the following technical solutions: a drug for hypercholesterolemia, the drug comprising a cholesterol absorption inhibitor and a bile acid chelating agent;

[0008] The cholesterol absorption inhibitor includes glutaric anhydride and fluorobenzene;

[0009] The bile sequestrant comprises a base polymer, a cross-linking agent and a functional monomer.

[0010] Preferably, the base polymer is any one of polyvinyl alcohol (PVA) and polyacrylamide (PAM), the cross-linking agent is any one of glutaraldehyde and epichlorohydrin, and the functional monomer is any one of amino, carboxyl, sulfonic acid, acrylamide and acrylic acid.

[0011] The present invention also provides a method for preparing a drug for treating hypercholesterolemia, comprising the following steps:

[0012] S1. Cholesterol absorption inhibitors

[0013] Add glutaric anhydride and fluorobenzene into a reaction tank, perform Friedel-Crafts reaction on glutaric anhydride and fluorobenzene, and obtain (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one after Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis, and lactonization. (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one reacts with 4-benzyloxybenzylidene-4-fluoroaniline to obtain trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone. Debenzylation and resolution of trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone give a cholesterol absorption inhibitor.

[0014] S2. Preparation of bile sequestrant

[0015] A1. First, pre-treat the base polymer, including dissolution, filtration and deionization, to ensure the subsequent reaction proceeds smoothly;

[0016] A2. According to the structure and performance requirements of the target product, reasonable polymerization reaction conditions are designed, including reaction temperature, pressure, time and the feeding ratio of monomer to initiator. Then, the base polymer is added to the reaction tank, and water is added to form a polymer solution. The cross-linking agent is slowly added dropwise to the polymer solution to control the rate and degree of the cross-linking reaction to avoid excessive cross-linking leading to hardening or embrittlement of the resin;

[0017] A3, introducing the functional monomer into the resin structure by graft copolymerization to ensure that the groups in the functional monomer are evenly distributed;

[0018] A4, spray drying and extrusion granulation of the cross-linked resin solution to form particles with uniform particle size;

[0019] A5. Washing, filtering and purifying the formed particles to remove unreacted monomers, cross-linking agents and impurities to obtain a bile sequestrant;

[0020] S3. Preparation of drugs for treating hypercholesterolemia

[0021] The prepared cholesterol absorption inhibitor and bile sequestrant are added into a blender, and an emulsifier is added, the cholesterol absorption inhibitor, bile sequestrant and emulsifier are stirred and mixed evenly, and then extruded and granulated to obtain a hypercholesterolemia drug.

[0022] Preferably, in A2 of S2, the temperature of the cross-linking reaction is 40-60° C., and the effect of the cross-linking reaction is evaluated by infrared spectroscopy analysis.

[0023] Preferably, in A4 of S2, the spray drying temperature is 120-150°C, the wind speed is 40-60m / s, and the pressure is 0.5-1.5MPa.

[0024] Preferably, in A5 of S2, vacuum drying is used to completely remove moisture and residual solvent in the particles to ensure dryness and stability.

[0025] Preferably, in S3, the emulsifier is any one of MC and gum arabic, and the ratio of the cholesterol absorption inhibitor, bile sequestrant and emulsifier is 1:3.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] 1. In the present invention, the cholesterol absorption inhibitor is prepared by Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis and lactonization reaction of glutaric anhydride and fluorobenzene, which reduces the difficulty of synthesizing the cholesterol absorption inhibitor and thus improves the preparation cost of the hypercholesterolemia drug;

[0028] 2. In the present invention, the bile sequestrant prepared from the base polymer, the cross-linking agent and the functional monomer can better control the excessive secretion of bile acid, improve the functionality of bile acid, avoid the occurrence of gallstones, and avoid excessive absorption of bile acid into the blood, thereby improving the effect of the prepared hypercholesterolemia drug, improving cardiovascular health, and reducing the risk of cardiovascular disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 The present invention is a flow chart for preparing a drug for treating hypercholesterolemia. DETAILED DESCRIPTION

[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Example: Figure 1As shown, the present invention provides a drug for hypercholesterolemia, the drug comprising a cholesterol absorption inhibitor and a bile acid sequestrant;

[0033] Cholesterol absorption inhibitors include glutaric anhydride and fluorobenzene;

[0034] The bile sequestrant comprises a base polymer, a cross-linking agent and a functional monomer, wherein the base polymer is polyvinyl alcohol (PVA), the cross-linking agent is epichlorohydrin, and the functional monomer is a carboxyl group.

[0035] The present invention also provides a method for preparing a drug for treating hypercholesterolemia, comprising the following steps:

[0036] S1. Cholesterol absorption inhibitors

[0037] Add glutaric anhydride and fluorobenzene into a reaction tank, perform Friedel-Crafts reaction on glutaric anhydride and fluorobenzene, and obtain (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one after Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis, and lactonization. (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one reacts with 4-benzyloxybenzylidene-4-fluoroaniline to obtain trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone. Debenzylation and resolution of trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone give a cholesterol absorption inhibitor.

[0038] S2. Preparation of bile sequestrant

[0039] A1. First, pre-treat the base polymer, including dissolution, filtration and deionization, to ensure the subsequent reaction proceeds smoothly;

[0040] A2. According to the structure and performance requirements of the target product, reasonable polymerization reaction conditions are designed, including reaction temperature, pressure, time and the feeding ratio of monomer to initiator. Then, the base polymer is added to the reaction tank, and water is added to form a polymer solution. The cross-linking agent is slowly added dropwise to the polymer solution to control the rate and degree of the cross-linking reaction to avoid excessive cross-linking leading to hardening or embrittlement of the resin;

[0041] A3, introducing the functional monomer into the resin structure by graft copolymerization to ensure that the groups in the functional monomer are evenly distributed;

[0042] A4, spray drying and extrusion granulation of the cross-linked resin solution to form particles with uniform particle size;

[0043] A5. Washing, filtering and purifying the formed particles to remove unreacted monomers, cross-linking agents and impurities to obtain a bile sequestrant;

[0044] S3. Preparation of drugs for treating hypercholesterolemia

[0045] The prepared cholesterol absorption inhibitor and bile sequestrant are added into a blender, and an emulsifier is added, the cholesterol absorption inhibitor, bile sequestrant and emulsifier are stirred and mixed evenly, and then extruded and granulated to obtain a hypercholesterolemia drug.

[0046] In A2 of S2, the temperature of the cross-linking reaction was 45°C, and the effect of the cross-linking reaction was evaluated by infrared spectroscopy analysis.

[0047] In A4 of S2, the spray drying temperature was 120°C, the wind speed was 50 m / s, and the pressure was 1 MPa.

[0048] In S2's A5, vacuum drying is used to completely remove moisture and residual solvents from the particles to ensure dryness and stability.

[0049] In S3, the emulsifier is MC, and the ratio of cholesterol absorption inhibitor, bile sequestrant and emulsifier is 1:3.

[0050] Example 2: A drug for hypercholesterolemia, comprising a cholesterol absorption inhibitor and a bile acid sequestrant;

[0051] Cholesterol absorption inhibitors include glutaric anhydride and fluorobenzene;

[0052] The bile sequestrant comprises a base polymer, a cross-linking agent and a functional monomer, wherein the base polymer is polyacrylamide (PAM), the cross-linking agent is glutaraldehyde and the functional monomer is acrylamide.

[0053] The present invention also provides a method for preparing a drug for treating hypercholesterolemia, comprising the following steps:

[0054] S1. Cholesterol absorption inhibitors

[0055] Add glutaric anhydride and fluorobenzene into a reaction tank, perform Friedel-Crafts reaction on glutaric anhydride and fluorobenzene, and obtain (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one after Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis, and lactonization. (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one reacts with 4-benzyloxybenzylidene-4-fluoroaniline to obtain trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone. Debenzylation and resolution of trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone give a cholesterol absorption inhibitor.

[0056] S2. Preparation of bile sequestrant

[0057] A1. First, pre-treat the base polymer, including dissolution, filtration and deionization, to ensure the subsequent reaction proceeds smoothly;

[0058] A2. According to the structure and performance requirements of the target product, reasonable polymerization reaction conditions are designed, including reaction temperature, pressure, time and the feeding ratio of monomer to initiator. Then, the base polymer is added to the reaction tank, and water is added to form a polymer solution. The cross-linking agent is slowly added dropwise to the polymer solution to control the rate and degree of the cross-linking reaction to avoid excessive cross-linking leading to hardening or embrittlement of the resin;

[0059] A3, introducing the functional monomer into the resin structure by graft copolymerization to ensure that the groups in the functional monomer are evenly distributed;

[0060] A4, spray drying and extrusion granulation of the cross-linked resin solution to form particles with uniform particle size;

[0061] A5. Washing, filtering and purifying the formed particles to remove unreacted monomers, cross-linking agents and impurities to obtain a bile sequestrant;

[0062] S3. Preparation of drugs for treating hypercholesterolemia

[0063] The prepared cholesterol absorption inhibitor and bile sequestrant are added into a blender, and an emulsifier is added, the cholesterol absorption inhibitor, bile sequestrant and emulsifier are stirred and mixed evenly, and then extruded and granulated to obtain a hypercholesterolemia drug.

[0064] In A2 of S2, the temperature of the cross-linking reaction was 60°C, and the effect of the cross-linking reaction was evaluated by infrared spectroscopy analysis.

[0065] In A4 of S2, the spray drying temperature was 150°C, the wind speed was 55 m / s, and the pressure was 1.5 MPa.

[0066] In S2's A5, vacuum drying is used to completely remove moisture and residual solvents from the particles to ensure dryness and stability.

[0067] In S3, the emulsifier is gum arabic, and the ratio of cholesterol absorption inhibitor, bile sequestrant and emulsifier is 1:3.

[0068] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A drug for treating hypercholesterolemia, characterized in that: The drugs include cholesterol absorption inhibitors and bile acid sequestrants; The cholesterol absorption inhibitor includes glutaric anhydride and fluorobenzene; The bile sequestrant comprises a base polymer, a cross-linking agent and a functional monomer.

2. The drug for treating hypercholesterolemia according to claim 1, characterized in that: The base polymer is any one of polyvinyl alcohol (PVA) and polyacrylamide (PAM), the crosslinking agent is any one of glutaraldehyde and epichlorohydrin, and the functional monomer is any one of amino group, carboxyl group, sulfonic acid group, acrylamide and acrylic acid.

3. A method for preparing a drug for treating hypercholesterolemia according to any one of claims 1 to 2, characterized in that: The following steps are involved: S1. Cholesterol absorption inhibitors Add glutaric anhydride and fluorobenzene into a reaction tank, perform Friedel-Crafts reaction on glutaric anhydride and fluorobenzene, and obtain (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one after Friedel-Crafts reaction, esterification, carbonyl reduction, hydrolysis, and lactonization. (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one reacts with 4-benzyloxybenzylidene-4-fluoroaniline to obtain trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone. Debenzylation and resolution of trans-1-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl)-4-(4-benzyloxyphenyl)2-azetidinone give a cholesterol absorption inhibitor. S2. Preparation of bile sequestrant A1. First, pre-treat the base polymer, including dissolution, filtration and deionization, to ensure the subsequent reaction proceeds smoothly; A2. According to the structure and performance requirements of the target product, reasonable polymerization reaction conditions are designed, including reaction temperature, pressure, time and the feeding ratio of monomer to initiator. Then, the base polymer is added to the reaction tank, and water is added to form a polymer solution. The cross-linking agent is slowly added dropwise to the polymer solution to control the rate and degree of the cross-linking reaction to avoid excessive cross-linking leading to hardening or embrittlement of the resin; A3, introducing the functional monomer into the resin structure by graft copolymerization to ensure that the groups in the functional monomer are evenly distributed; A4, spray drying and extrusion granulation of the cross-linked resin solution to form particles with uniform particle size; A5. Washing, filtering and purifying the formed particles to remove unreacted monomers, cross-linking agents and impurities to obtain a bile sequestrant; S3. Preparation of drugs for treating hypercholesterolemia The prepared cholesterol absorption inhibitor and bile sequestrant are added into a blender, and an emulsifier is added, the cholesterol absorption inhibitor, bile sequestrant and emulsifier are stirred and mixed evenly, and then extruded and granulated to obtain a hypercholesterolemia drug.

4. The method for preparing a drug for treating hypercholesterolemia according to claim 3, characterized in that: In A2 of S2, the temperature of the cross-linking reaction is 40-60° C., and the effect of the cross-linking reaction is evaluated by infrared spectroscopy analysis.

5. The method for preparing a drug for treating hypercholesterolemia according to claim 3, characterized in that: In A4 of S2, the spray drying temperature is 120-150°C, the wind speed is 40-60m / s, and the pressure is 0.5-1.5MPa.

6. The method for preparing a drug for treating hypercholesterolemia according to claim 3, characterized in that: In S2's A5, vacuum drying is used to completely remove moisture and residual solvents from the particles to ensure dryness and stability.

7. The method for preparing a drug for treating hypercholesterolemia according to claim 3, characterized in that: In S3, the emulsifier is any one of MC and gum arabic, and the ratio of the cholesterol absorption inhibitor, bile sequestrant and emulsifier is 1:3.

Citation Information

Cited By

  • Slow-release fat powder for pigs and preparation method thereof

    CN120678166A